 |
|
New genetic test predicts risk of metastasis in patients with deadly eye cancer
November 15, 2006UCLA surgeons first to biopsy tumor tissue from living eye
Imagine being diagnosed with eye cancer - but your doctor can't tell whether you have the aggressive type that will swiftly spread, causing blindness and death in as early as a year.
A new procedure at UCLA's Jules Stein Eye Institute could reveal this valuable information to ocular melanoma patients and their physicians, providing a clear basis for making treatment and lifestyle choices. Researchers have pioneered the first technique to biopsy tissue from the living eye in order to predict which tumors possess high metastatic risk. The Nov. 15 online edition of the journal Ophthalmology reports the findings, which urge a new treatment strategy for physicians and offer huge medical and psychological benefits to patients.
"For the first time, we have demonstrated that it's safe and feasible to perform a biopsy in the living eye to obtain clear results about whether a tumor has metastatic potential or not," explained Dr. Tara Young, assistant professor of ophthalmology at UCLA's Jules Stein Eye Institute and a Jonsson Comprehensive Cancer Center researcher. "Identifying patients at high risk for metastasis is an important first step toward reducing the death rate of this cancer, which kills nearly half of its patients."
Ocular melanoma attacks the pigment cells in the retina. Earlier studies discovered that patients who are missing one copy of chromosome 3 in their tumor tissue are more likely to have highly aggressive cancers. Half of these patients die within five years, due to metastasis to the liver and other organs.
Using this genetic marker as the starting point for their research, UCLA scientists studied a group of patients who had been newly diagnosed with ocular melanoma. Each patient was scheduled for a standard eye surgery to temporarily implant a small disc designed to shrink the tumor with radiation and hopefully save the eye.
For the first time, UCLA surgeons used an ultra-fine needle to collect cells from the cancer before surgery and send the sample to the lab for culture. After growing the tumor cells, a geneticist analyzed them to determine whether they were missing a copy of chromosome 3.
Of the nine patients in the UCLA study who underwent biopsy, four had tumors identified as high-risk for aggressive metastasis, and five were identified as low-risk.
"When physicians know upfront which patient has a poor prognosis, they will monitor the person more closely to detect metastasis earlier and consider more aggressive treatments to increase their chance of survival," Young emphasized. "Knowledge of metastatic risk will also help patients and their physicians decide whether to pursue clinical trials of experimental therapies that target metastasis.
"Patients understand that no good treatment exists after their cancer spreads - everyone wants to know what their metastasis risk is," she added. "If the risk is low, it's a giant relief and emotional burden off their shoulders. If the risk is high, it enables them to plan arrangements for their family and finances, and make the most of their remaining time alive."
Pioneered by UCLA ophthalmic pathologist Dr. Ben Glasgow, the technique of fine-needle aspiration for collecting cancer cells from the living eye has been the standard of care at the Jules Stein Eye Institute since 2004, but adopted by only a handful of other ophthalmic centers in the nation.
"Until now, there's been little we could do but radiate the patient's eye and ask them to return for a follow-up exam in six months," observed Young. "But it's short-sighted to think of ocular melanoma as related only to the eyeball. Cancer can kill you, regardless of where it originates in the body.
"We've known for 10 years that this genetic marker is linked to fast-growing melanoma," she added. "It's time for ophthalmologists to expand their surgical practice to include the biopsy procedure, and use it to obtain life-saving information for their patients. Only then will we be able to develop strategic approaches to treating the cancer's effect on the whole body."
Although rare, ocular melanoma is the most common eye cancer to strike adults. The National Eye Institute reports some 2,000 newly diagnosed cases of the cancer - roughly seven in 1 million people - per year in the United States and Canada. The disease spans the age and ethnic spectrum, and is not hereditary.
University of California - Los Angeles
"For the first time, we have demonstrated that it's safe and feasible to perform a biopsy in the living eye to obtain clear results about whether a tumor has metastatic potential or not," explained Dr. Tara Young, assistant professor of ophthalmology at UCLA's Jules Stein Eye Institute and a Jonsson Comprehensive Cancer Center researcher. "Identifying patients at high risk for metastasis is an important first step toward reducing the death rate of this cancer, which kills nearly half of its patients."
Ocular melanoma attacks the pigment cells in the retina. Earlier studies discovered that patients who are missing one copy of chromosome 3 in their tumor tissue are more likely to have highly aggressive cancers. Half of these patients die within five years, due to metastasis to the liver and other organs.
Using this genetic marker as the starting point for their research, UCLA scientists studied a group of patients who had been newly diagnosed with ocular melanoma. Each patient was scheduled for a standard eye surgery to temporarily implant a small disc designed to shrink the tumor with radiation and hopefully save the eye.
For the first time, UCLA surgeons used an ultra-fine needle to collect cells from the cancer before surgery and send the sample to the lab for culture. After growing the tumor cells, a geneticist analyzed them to determine whether they were missing a copy of chromosome 3.
Of the nine patients in the UCLA study who underwent biopsy, four had tumors identified as high-risk for aggressive metastasis, and five were identified as low-risk.
"When physicians know upfront which patient has a poor prognosis, they will monitor the person more closely to detect metastasis earlier and consider more aggressive treatments to increase their chance of survival," Young emphasized. "Knowledge of metastatic risk will also help patients and their physicians decide whether to pursue clinical trials of experimental therapies that target metastasis.
"Patients understand that no good treatment exists after their cancer spreads - everyone wants to know what their metastasis risk is," she added. "If the risk is low, it's a giant relief and emotional burden off their shoulders. If the risk is high, it enables them to plan arrangements for their family and finances, and make the most of their remaining time alive."
Pioneered by UCLA ophthalmic pathologist Dr. Ben Glasgow, the technique of fine-needle aspiration for collecting cancer cells from the living eye has been the standard of care at the Jules Stein Eye Institute since 2004, but adopted by only a handful of other ophthalmic centers in the nation.
"Until now, there's been little we could do but radiate the patient's eye and ask them to return for a follow-up exam in six months," observed Young. "But it's short-sighted to think of ocular melanoma as related only to the eyeball. Cancer can kill you, regardless of where it originates in the body.
"We've known for 10 years that this genetic marker is linked to fast-growing melanoma," she added. "It's time for ophthalmologists to expand their surgical practice to include the biopsy procedure, and use it to obtain life-saving information for their patients. Only then will we be able to develop strategic approaches to treating the cancer's effect on the whole body."
Although rare, ocular melanoma is the most common eye cancer to strike adults. The National Eye Institute reports some 2,000 newly diagnosed cases of the cancer - roughly seven in 1 million people - per year in the United States and Canada. The disease spans the age and ethnic spectrum, and is not hereditary.
University of California - Los Angeles
Eye Cancer Current Events and Eye Cancer News RSSSt. Jude defines eye cancer gene's role in retinal development
A genetic discovery led by scientists at St. Jude Children's Research Hospital helps answer a long-standing mystery about the eyes of vertebrates, and may translate into a deeper understanding of how genes coordinate the complex process of eye formation and how a rare pediatric eye cancer progresses.
St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory
Investigators at St. Jude Children's Research Hospital have identified the cell that gives rise to the eye cancer retinoblastoma, disproving a long-standing principle of nerve growth and development.
Immune deficiency linked to a type of eye cancer
The incidence of squamous cell eye cancer is greater among kidney transplant patients and people with human immunodeficiency virus (HIV) than the general public, which suggests the disease is associated with immune deficiency.
St. Jude announces breakthrough in eye cancer treatment
Scientists at St. Jude Children's Research Hospital have demonstrated in a mouse model a new, locally applied treatment for the eye cancer retinoblastoma that not only greatly reduces the size of the tumor, but does so without causing the side effects common with standard chemotherapy.
Genetic insights may explain retinal growth, eye cancer
Investigators at St. Jude Children's Research Hospital have discovered the role of several key genes in the development of the retina, and in the process have taken a significant step toward understanding how to prevent or cure the potentially deadly eye cancer retinoblastoma.
Radiation therapy can help spare vision in patients with melanoma of the eye
Treating a rare form of eye cancer with radiation therapy can spare patients from significant vision loss.
Retinoblastoma researchers find success with two-drug combination
Retinoblastoma is a tumor that arises in the cells of the retina, the light-sensitive tissue at the back of the eyeball, following mutation of the gene RB1.
More Eye Cancer Current Events and Eye Cancer News Articles
 | Living With Cancer as "A New Normal": A Journey with Cancer through the Eyes of a Caregiver by Dianna Mitchell Marston Dianna Mitchell Marston, Author: She has 6 years of hands-on experience while care giving for her husband as they discovered Living With Cancer as “A New Normal”. Through research and medical conferences she discovered many options for cancer treatments and care giving from around the world which include chemotherapy, radiation, bone marrow transplants, nutritional options, spiritual and... |
 | Tumors of the Eye and Ocular Adnexa (Atlas of Clinical Oncology) by Devron H. Char American Cancer Society Atlas of Clinical Oncology ACS Tumors of the Eye and Ocular Adnexa Tumors of the Eye and Ocular Adnexa is an authoritative and comprehensive colour atlas that will serve the resource needs of the student and the practitioner involved in the treatment of tumors of the eye, orbit, and periorbital structures - lids, lacrinal glands, and adnaxae. The atlas covers basic... |
 | The Official Patient's Sourcebook on Intraocular Melanoma: A Revised and Updated Directory for the Internet Age by Icon Health Publications This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to intraocular melanoma (also eye cancer; Eye tumor; Malignant melanoma... |
| Protect Your Life in the Sun: How to Minimize Your Exposure to Ultraviolet Sunlight and Prevent Skin Cancer and Eye Disorders by Paul L. Gourley, Gail M. Gourley | |
| walking in the light, poetry and essays reflecting life experiences as seen through the eyes of a cancer survivor | |
 | Cancer Through the Eyes of Ten Women |
| A DISSERTATION UPON THE CANCER OF THE EYE-LIDS, NOSE, GREAT ANGLE OF THE EYE, AND ITS NEIGHBOURING PARTS, COMMONLY CALLED THE NOLI-ME-TANGERE, DEEMED HITHERTO INCURABLE BOTH ANTIENTS AND MODERNS, BUT NOW SHEWN TO BE AS CURABLE AS OTHER DISTEMPERS. by Jacques. DAVIEL | |
| Walking in the Light... : Poetry and Essays Reflecting Life Experiences as Seen Through the Eyes of a Cancer Survivor by Blaine Thorson | |
 | Eye Cancer Research Progress |
| Gale Encyclopedia of Medicine: Eye cancer by Ronald Scott Watson PhD The article is excerpted from Gale Encyclopedia of Medicine. Consult the second edition of this authoritative, comprehensive, in-depth medical guide for information on more than 1,700 medical topics in language accessible to adult laypersons. Presented in a single alphabetical sequence, articles range in length from one or two paragraphs for minor topics, to several pages or more for major... |
| © 2008 BrightSurf.com |